Skip to content

Ketamine research published in 2013

Page 2 of 2: studies 21 to 26 of 26, newest first. Back to the ketamine overview

Studies

Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)

CNS Neuroscience & Therapeutics April 10, 2013 G. Mion, Thierry Villevieille 690 citations

For more than 50 years, ketamine has proven to be a safe anesthetic drug with potent analgesic properties. The active enantiomer is S(+)-ketamine. Ketamine is mostly metabolized in norketamine, an active metabolite. During "dissociative anesthesia", sensory inputs may reach cortical receiving areas, but fail to be perceived in some association areas. Ketamine also enhances the descending...

DOI: 10.1111/cns.12099 (opens in new tab) Ketamine Nmda receptor Pharmacology Analgesic +8

Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Psychopharmacology March 1, 2013 Lawrence P Carter, Bethea A Kleykamp, Roland R. Griffiths et al. 19 citations

Several studies have documented impairments in memory processes as a result of ketamine administration; however, few studies have compared the profile of cognitive effects of ketamine to other drugs. The aim of this study was to compare the cognitive effects of ketamine with those of triazolam in healthy volunteers. Doses of ketamine (0.2, 0.4 mg/kg intramuscular (i.m.)), triazolam (0.2, 0.4...

DOI: 10.1007/s00213-012-2883-x (opens in new tab) Full text (opens in new tab) Cognitive impairment Memory impairment Cognitive dysfunction Mental decline +28

Ketamine for chronic pain: risks and benefits

British Journal of Clinical Pharmacology February 21, 2013 Marieke Niesters, Christian H. Martini, Albert Dahan 498 citations

The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those that have a neuropathic component. Low dose ketamine produces strong analgesia in neuropathic pain states, presumably by inhibition of the N-methyl-D-aspartate receptor although other mechanisms are possibly involved, including enhancement of descending inhibition and anti-inflammatory effects at central...

Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor SB216763, in the Chronic Mild Stress Model of Mice

PLoS One February 4, 2013 Xiancang Ma, Yonghui Dang, Min Jia et al. 115 citations

BACKGROUND: Clinical studies demonstrate that the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, induces rapid antidepressant effects in patients with refractive major depressive disorder and bipolar depression. This rapid onset of action makes ketamine a highly attractive drug for patients, particularly those who do not typically respond to therapy. A recent study suggested that...

DOI: 10.1371/journal.pone.0056053 (opens in new tab) Ketamine Tail suspension test Pharmacology Behavioural despair test +11

Ketamine for the Treatment of Depression

Journal of Psychosocial Nursing and Mental Health Services 2013 Robert H Howland

Ketamine (Ketalar®) is an anesthetic agent derived from the hallucinogenic drug phencyclidine (PCP). It is a high-affinity antagonist at N-methyl-D-aspartate receptors and also binds to opioid mu and sigma receptors. Ketamine is being intensively investigated as an antidepressant therapy. To date, five short-term controlled studies and other open-label studies in patients with unipolar or...

Differential behavioral effects of ketamine between adolescent and adult Sprague-Dawley rats

VCU Scholars Compass 2013 Maria A. Greenwood 1 citation

The dissociative anesthetic ketamine has been subject to growing abuse worldwide, particularly in adolescents. This project compared the effects of ketamine in conditioned place preference and intravenous self-administration in adolescent (PND 28-50) and adult (>PND70) Sprague-Dawley rats. Cocaine served as a positive control. In CPP, adolescents demonstrated preferences for ketamine, while...